| Name | OPC-28326 |
| Description | OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively. |
| In vitro | OPC-28326 augments microvessel growth and improves endothelial tube formation. OPC-28326 dose-dependently induces phosphorylation of eNOS and Akt without affecting total amounts of eNOS and Akt in HAECs[1]. |
| In vivo | OPC-28326 improves blood flow recovery in murine hindlimb ischemia and increases the number of capillaries in the ischemic leg[1]. In rats, intravenous administration of OPC-28326 (3 - 30 mg/kg) and yohimbine (0.3 - 3 mg/kg) results in a dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920 without affecting the mydriasis[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.22 mg/mL (10.01 mM), Sonication is recommended.
|
| Keywords | α2C-adrenoceptor | α2C adrenoceptor | α2B-adrenergic receptor | α2B adrenoceptor | α2A-adrenergic receptor | α2A adrenoceptor | OPC-28326 | OPC28326 | OPC 28326 | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Compound Library |
United States
